BenevolentAI

ulcerative colitis

First patients dosed with an AI-derived target for ulcerative colitis 

5 September 2023

BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024.  UC is a chronic disease that causes inflammation and ulceration of the inner […]

""

BenevolentAI progresses drug for the potential treatment of ALS 

6 June 2023

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS).  BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies.  Impaired retinoic acid signalling has been […]